drugset / Trial / NCT05887609
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
Non-randomizedSequentialOpen-labelTreatment
Summary
The Principal Investigator hypothesizes the combination of MIRV and Olaparib is an effective, and tolerable, maintenance therapy strategy in platinum sensitive recurrent ovarian cancer.
Timeline
- Start
- 2023-10-03
- Primary completion
- 2029-01-31
- Completion
- 2031-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirvetuximab Soravtansine | Other / unclassified | 5 mg/kg | Intravenous |
| Subject | Olaparib | Small molecule | 300 mg | Oral |